Nasdaq · Biotech stocks database
BOLD (Boundless Bio Inc.) stock: $2.40, $55.6M market cap, $62.9M cash, -$7.3M EV, $70.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We expect to have initial proof-of-concept safety and efficacy clinical data from the KOMODO-1 trial of BBI-940 within our existing cash runway timeline discussed below. We have been investigating BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 designed to target replication stress in oncogene amplified cancers, and BBI-825, a novel oral, selective inhibitor of ribonucleotide reductase, in the clinic in the POTENTIATE trial and the STARMAP trial.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $62.9M |
|---|---|
| Debt | $0.0M |
| Net cash | $62.9M |
| Enterprise value | -$7.3M |
| Basic shares | 23.6M shares |
| Fully diluted shares | 29.2M shares |
| Fully diluted market cap | $70.0M |
| Cash per share | $2.66 |
| Quarterly burn | $21.0M |
| Cash runway | 3.5 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.
Cap table as of 2026-08-05.
Loading BOLD daily closes…